Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maridebart cafraglutide in obesity in Japan
NCT06987695Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Jun 2025
- Primary completion
- Apr 2027
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of maridebart cafraglutide in obesity, sponsored by Amgen. Started Jun 2025; status: active, not recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06987695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06987695.